Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Amgen (AMGN) to Report Q2 Earnings: Here's What to Expect

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether certain directors and officers of Amgen Inc. (“Amgen”) (NASDAQ: AMGN) breached their fiduciary duties to Amgen and its shareholders. If you are an Amgen shareholder, you may contact attorney Joe Pettigrew for additional information toll-free at 844-818-6982, or jpettigrew@scott-scott.com. Scott+Scott is investigating whether membe.

INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Amgen Inc's Directors and Officers for Breach of Fiduciary Duties – AMGN

Apple

Broadcom

Blackrock Inc

Bristol-Myers

Carrier Global

Caterpillar

Chubb

Comcast

Cisco Systems

Dick's Sporting Goods

General Mills

HSBC Holdings

iShares Core S&P 500 ETF

Johnson & Johnson

Juniper Networks

Kellogg

Kroger

Lowe's

Mondelez

Medtronic

Microsoft

QUALCOMM

Invesco QQQ

Invesco S&P 500 Equal Weight ETF

My U.S. dividend growth portfolio, constructed in 2015, has outperformed the market by over 2% annually. The portfolio was designed to be resilient in a major stock market correction, focusing on dividend achievers with at least 10 years of dividend growth. For building a similar portfolio in 2023, I considered valuation and growth, leaning towards larger cap or mega-cap stocks, and factored in retirement income needs.

Building The Dividend Growth Portfolio In 2023

Many high-yielding stocks are either too risky or too expensive. Amgen and Bristol Myers Squibb offer above-average dividend yields, attractive valuations, and a reasonable margin of safety.

2 Cheap High-Yield Dividend Stocks to Buy Now

Amgen is now down nearly 20% since last November as money continues to rotate from defensive sectors into tech. The biopharma company should benefit from the rapid emergence of biosimilars thanks to its strong pipeline. Its own GIPR and GLP-1 receptor agonists could also be a major growth driver if the development goes according to plan.

Amgen: Huge Potential With Biosimilars And GLP-1

GlaxoSmithKline

Pharma stocks experienced an abysmal first half due to various factors. Rotation from defensive to cyclical sectors, drug price negotiations and upcoming patent cliffs have muddied the outlook.

The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023

Salesforce

Goldman Sachs

Home Depot

Intel

JPMorgan Chase & Co

UnitedHealth Group

The Dow's 10-straight day rally keeps making history — it hasn't done this since at least 2017. And investors can thank a select group.

11 Stocks Drive The Dow's Amazing 10-Straight Day Rally

Arcturus Therapeutics

Roivant Sciences Ltd

The biotech industry is constantly evolving due to being on the cutting edge of the healthcare industry's research and development. Large biotech companies such as Johnson and Johnson (NYSE: JNJ ), Merck (NYSE: MRK ), and AbbVie (NYSE: ABBV ) offer investors steady and continual growth as well as decent dividends.

3 Biotech Stocks for Getting Rich in 2023

Pfizer

Amgen and Pfizer each possess admirable product portfolios and pipelines. Both companies sport dividend yields approaching 4% to nearly 5%.

2 Best Biotech Stocks to Buy Right Now

Since instituting a dividend program in 2011, Amgen stock has become a top passive income vehicle. Although the biotech is entering a period of slower growth, its dividend appears to be safe.

Is Amgen's Dividend Safe?

AbbVie

DiCE Molecules Holding LLC

Horizon Pharma

Eli Lilly

Seagen

The brisk pace of biopharmaceutical deal making seen in the first half of this year may only accelerate in the months ahead, even as regulators take a hard look at some of the bigger deals, analysts say.

Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say

Amazon

ANSYS

Alphabet

These companies have beaten the Rule of 40 year after year

Chevron

Dow Inc

Coca-Cola

Verizon

Walgreens

"The Dow if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.”–DowJones&Co. The highest-yield 10 stocks are June's Dogs of the Dow: KO, CSCO, GS, AMGN, CVX, IBM, DOW, MMM, WBA, and VZ, averaged a 4.79% annual yield. Thirty Dow stocks represent nine of eleven sectors. Dow Jones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated July net-gains ranged 14.83%-30.2%, topped by DIS 7/5/23.

Buy 3 July Dogs Of The Dow, Watch 6

AbbVie should survive the loss of exclusivity of its crown jewel, Humira. Amgen's struggles are real, but so is the company's ability to innovate.

2 Struggling Dividend Growth Stocks That Could Make You Richer

Amgen: Is The 3.79% Dividend Yield Worth The Fuss?

Agilent Technologies

Autodesk

Bank of America

Biogen

Bank of New York Mellon

CME Group

Compass Minerals

Campbell Soup

Copart

Cheniere Energy Partners

Corteva Inc

Disney

Domino's Pizza

Ecolab

Equifax

Estee Lauder

Emerson Electric

Etsy

General Dynamics

Gilead Sciences

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

U.S. Wide-Moat Stocks On Sale - The July 2023 Heat Map

News for Amgen Stock (AMGN)